These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22012605)

  • 41. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Omalizumab in patients with severe asthma: the XCLUSIVE study.
    Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
    Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
    Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
    Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimisation of omalizumab dosage in patients with severe persistent allergic asthma using recoveryELISA.
    Steiß JO; Becher G
    BioDrugs; 2014 Oct; 28(5):445-50. PubMed ID: 24898594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapy with omalizumab in patients with severe persistent allergic asthma: a real life data in Turkey].
    Bavbek S; Aydın O; Kepil Özdemir S; Yılmaz I; Celik GE; Demirel YS; Mungan D; Sin B; Kurşun N; Mısırlıgil Z
    Tuberk Toraks; 2010; 58(4):425-34. PubMed ID: 21341120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
    Corren J; Shapiro G; Reimann J; Deniz Y; Wong D; Adelman D; Togias A
    J Allergy Clin Immunol; 2008 Feb; 121(2):506-11. PubMed ID: 18269927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
    Hochhaus G; Brookman L; Fox H; Johnson C; Matthews J; Ren S; Deniz Y
    Curr Med Res Opin; 2003; 19(6):491-8. PubMed ID: 14594521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgE Immunoadsorption Knocks Down the Risk of Food-Related Anaphylaxis.
    Dahdah L; Ceccarelli S; Amendola S; Campagnano P; Cancrini C; Mazzina O; Fiocchi A
    Pediatrics; 2015 Dec; 136(6):e1617-20. PubMed ID: 26620068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Severe asthma, IgE and anti-IgE: from sceptical waiting to factual learning].
    Blanc FX
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):925-7. PubMed ID: 16220115
    [No Abstract]   [Full Text] [Related]  

  • 58. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R; Zheng Y; Putnam WS; Visich J; Eisner MD; Matthews JG; Rosen KE; D'Argenio DZ
    AAPS J; 2013 Apr; 15(2):559-70. PubMed ID: 23413101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
    Lowe PJ; Renard D
    Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.